TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Carnitine Infusion and Insulin Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* • Caucasian~  * Healthy (as determined by responsible physician based on a medical questionnaire)~ * Male~ * Age: 18-40 years~ * Normal BMI: 18-25 kg/m2~ * Stable dietary habits~ * No use of medication interfering with investigated study parameters (as determined by responsible physician)~Exclusion Criteria:~* • Female~  * Haemoglobin levels \< 7.8 mmol/L~ * Uncontrolled hypertension~ * Use of anticoagulants~ * Engagement in exercise \> 3 hours a week~ * Being vegetarian or vegan (because of altered whole body carnitine status)~ * Smoking~ * Alcohol and/or drug abuse~ * Unstable body weight (weight gain or loss \> 5kg in the last 3 months)~ * Significant food allergies/intolerances (seriously hampering study meals)~ * Participation in another biomedical study within 1 month before the first study visit, which would possibly hamper our study results~ * Medication use known to hamper subject's safety during the study procedures~ * Medication use known to interfere with investigated study parameters~ * Subjects with contra-indications for MRI~ * Subjects who intend to donate blood during the intervention or subjects who have donated blood less than three months before the start of the study~ * Subjects who do not want to be informed about unexpected medical findings~ * Subjects who do not want that their treating physician is informed

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- LIPID + Carnitor (Type: EXPERIMENTAL): intravenous Lipid infusion (IntraLipid) combined with carnitor (L-carnitine) infusion~L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.~Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h.
- LIPID + PLAC (Type: PLACEBO_COMPARATOR): Intravenous Lipid infusion (IntraLipid) combined with placebo infusion (saline)~Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h.
- PLAC (Type: PLACEBO_COMPARATOR): Infusion of saline (no IntraLipid and no carnitor)~Saline will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 ml/h.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Satiety, Meal Frequency and Nutritional Aspects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* No smokers~* BMI 20 to 35 kg/m2~* Moderate physical activity~* Safety during medical consultation~* Feeding behavioural phenotype (Dutch Eating Questionnaire, Three Eating Factor Questionnaire)~Exclusion Criteria:~* Medical history which may affect glucose metabolism (diabetes, renal or hepatic failure, thyroid dysfunction, Cushing syndrome, acromegaly...)~* Medical history which affect nutrient absorption (gastro-intestinal and pancreatic disease, gastrectomy, colectomy...)~* Drug use in the last two months that could affect glucose metabolism (steroids, topical gastric preparation, anorectic drugs...)~* Eating disorders~* Claustrophobic subjects

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- non-obese volunteers (Type: OTHER): Volunteers with a BMI (Body Mass Index) between 20 and 25 kg/m2.
- Obese volunteers (Type: OTHER): Volunteers with a BMI (Body Mass Index) between 30 and 35 kg/m2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: INCA: Intracranial Aneurysm Treatment With NeXsys

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80 years at screening~* Unruptured saccular IA in the anterior or posterior circulation with dimensions consistent with Table 2~* IA appears suitable for NeXsys device~* Patient willing to comply with study requirements~* Patient able to understand and sign a study-specific informed consent form~Exclusion Criteria:~* Ruptured IA~* Any other IA that requires treatment in the next year~* IA width \>10 mm~* IA neck \>9 mm~* IA has important flow from its base such that occluding the IA would cause stroke~* Target IA contains any device (e.g., coils)~* Inability to access the target IA with microcatheter~* Any congenital or iatrogenic coagulopathy~* Platelet count \<50,000/microliter~* Known allergy to platinum, nickel or titanium~* Known allergy to contrast agents~* Stenosis of the target IA's parent vessel \>50%~* Taking daily aspirin or other platelet inhibitor (clopidogrel or equivalent)~* Taking any anticoagulants (e.g., warfarin)~* Pregnant or planning pregnancy in the next 2 years~* Other medical conditions that could increase the risk of neurovascular procedures (e.g., liver failure, cancer, etc.)~* Participating in another study with investigational devices or drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Placement of study device (currently called NeXsys) into target aneurysm via standard endovascular procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CPAP and Lateral Neck Rotation on Anesthetized Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. MRI: Children requiring MRI examination with propofol sedation.~2. Bronchoscopy: Child requiring elective flexible bronchoscopy during general anesthesia. (1 child only) -~Exclusion Criteria:~1. Acute or chronic lung disease,~2. upper airway disease,~3. congestive heart failure,~4. obesity,~5. sleep apnea syndrome,~6. central nervous system disease likely to influence muscle tone,~7. any type of abnormality in head or neck anatomy, or~8. the requirement for any type of airway adjunct device (e.g., oral airway, endotracheal tube, etc.). -

- Gender: ALL
- Minimum Age: None
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): A convenience sample of children will be utilized for this study, which will include both genders and all ethnicities. There is no known predilection for any racial or gender inequalities with regard to subject recruitment or outcome variables related to this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion -~* Liver tumors treatable by SBRT not to exceed 10cm in greatest axial dimension.~  * 800 cc of uninvolved liver~ * Patients may have additional hepatic lesions if they are \<3cm and can be treated with TACE or RFA.~* Age \> 18 years old~* Albumin \> 2.4 g/dL.~* Total bilirubin \< 3 mg/dL.~* INR ≤ 1.5.~* Creatinine \< 2.0 mg/dL.~* Confirmed hepatocellular carcinoma by one of the following:~  * Histopathology~ * Two radiographic techniques (out of US, MRI, CT, Angiography) that confirm a lesion \>2 cm with arterial hypervascularization~ * One radiographic technique that confirms a lesion \>2 cm with arterial hypervascularization and an elevated AFP~* Hepatic lesion in patients for whom surgical resection is not possible or would not result in an opportunity for cure~* Tumor(s) \<10cm~* Eastern Clinical Oncology Group performance status 0, 1 or 2~* No prior surgery, chemotherapy, or radiation for the current tumor~* Patients placed on the liver transplant registry are eligible for this trial, but will be withdrawn from the protocol if they receive liver transplantation.~* TACE done prior to study enrollment is allowed if there were no more than 3 procedures within an 18 week period and SBRT can begin within 12 weeks of the last TACE procedure.~Exclusion -~* Prior radiotherapy to the upper abdomen~* Prior TACE, RFA, or liver transplant~* Tumor(s) ≥ 10cm~* Large esophageal varices without band ligation~* Active GI bleed or within 2 weeks of study enrollment~* Ascites refractory to medical therapy~* Contraindication to receiving radiotherapy~* Women who are pregnant~* Administration of any systemic cytotoxic agents within the last 12 months~* Presence of extrahepatic metastases~* Participation in another concurrent treatment protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stereotactic body radiotherapy (SBRT) (Type: EXPERIMENTAL): SBRT will be delivered on Varian's linear accelerator with On-Board Imaging (OBI) capabilities. The tumor will be tracked with the ethiodol material from the TACE procedure, and respiratory gating will be used to minimize motion due to respiration. Treatment will be given in either 3 or 5 fractions . SBRT will take place after the treatment planning and within 12 weeks of the last TACE procedure.~Doses: 45 Gy at 15 Gy/fraction , 36 Gy at 12 Gy/fraction, 45 Gy at 9 Gy/fraction, 40 Gy at 8 Gy/fraction

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis: Newly diagnosed symptomatic multiple myeloma~* Signed informed consent~* No second tumors~Exclusion Criteria:~* Monoclonal gammopathies of undefined significance~* Smoldering Multiple Myeloma~* Plasma cell leukemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topical Multiple Ascending Dose Study for PF-06423264

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 18.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and female of non-childbearing potential;~* Body Mass Index 17.5-35.5 kg/m2;~* Body weight \>50 kg;~Exclusion Criteria:~* Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergises, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Part A_Cohort 1_Active (Type: EXPERIMENTAL): Multiple ascending dose of PF-06423264
- Part A_Cohort 1_Placebo (Type: PLACEBO_COMPARATOR): Multiple dose of placebo
- Part A_Cohort 2_Active (Type: EXPERIMENTAL): Multiple ascending dose of PF-06423264
- Part A_Cohort 2_Placebo (Type: PLACEBO_COMPARATOR): Multiple dose of placebo
- Part A_Cohort 3_Active (Type: EXPERIMENTAL): Multiple ascending dose of PF-06423264
- Part A_Cohort 3_Placebo (Type: PLACEBO_COMPARATOR): Multiple dose of placebo
- Part A_Cohort 4_Active (Type: EXPERIMENTAL): Multiple ascending dose of PF-06423264
- Part A_Cohort 4_Placebo (Type: PLACEBO_COMPARATOR): Multiple dose of placebo
- Part A_Cohort 5_Active (Type: EXPERIMENTAL): Multiple ascending dose of PF-06423264
- Part A_Cohort 5_Placebo (Type: PLACEBO_COMPARATOR): Multiple dose of placebo
- Part A_Cohort 6_Active (Type: EXPERIMENTAL): Multiple ascending dose of PF-06423264
- Part A_Cohort 6_Placebo (Type: PLACEBO_COMPARATOR): Multiple dose of placebo
- Part A_Cohort 7_Active (Type: EXPERIMENTAL): Multiple ascending dose of PF-06423264
- Part A_Cohort 7_Placebo (Type: PLACEBO_COMPARATOR): Multiple ascending dose of placebo
- Part B_Cohort 1_Active (Type: EXPERIMENTAL): Multiple doses of PF-06423264
- Part B_Cohort 1_Placebo (Type: PLACEBO_COMPARATOR): Multiple doses of placebo
- Part B_Cohort 2_Active (Type: EXPERIMENTAL): Multiple doses of PF-06423264
- Part B_Cohort 2_Placebo (Type: PLACEBO_COMPARATOR): Multiple doses of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Lumbar Erector Spinae Plane Block for Hip Arthroplasty at the L4 Interspace

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing primary hip arthroplasty~* American Society of Anesthesiologists (ASA) Category 1, 2, and 3~* Patients age ≥18 years~Exclusion Criteria:~* Patient refusal~* Inability to understand and sign consent~* Infection at the injection site~* Known allergy or hypersensitivity to ropivacaine or other amide local anesthetics~* Contraindication or patient refusal to get spinal anesthesia~* Thrombocytopenia (platelets \< 100,000)~* Coagulopathy (INR \> 1.4)~* Use of anticoagulant drugs that have not been discontinued in an appropriate amount of time before the surgery~* ASA Category 4 and 5

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Ultrasound-guided Erector Spinae Block (Type: None): Patients will then be randomized into one of the two groups above. One group will receive a lumbar erector spinae block at L4 with 30ml of 0.375% ropivacaine with 50 mcg of dexmedetomidine before the procedure using ultrasound guidance. The second group will receive no peripheral nerve block to serve as the control. All patients receiving nerve blocks will have a printed image of the block thus to confirm proper spread of local anesthetic both cranially and caudally.
- No Ultrasound-guided Erector Spinae Block (Type: None): Patients with no peripheral nerve block to serve as the control.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients Treated for Classical HODgkin's Lymphoma.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient at least 18 years of age~* Patient for whom anti-PD-1 antibody therapy (nivolumab or pembrolizumab) is given as monotherapy for relapsed or refractory classical Hodgkin's lymphoma within the scope of the WMA.~* Patient for whom a PET-CT for the evaluation of TMTV is available within 30 days prior to the first treatment without intercurrent antitumour therapy between the last PET-CT and the start of anti-PD1 treatment.~* For women of childbearing age, use of effective contraception~* Patient with free, informed and written consent~* Patient affiliated to a social security scheme~Exclusion Criteria:~* Persons of full age subject to legal protection (judicial protection, guardianship, trusteeship), persons deprived of their liberty, pregnant or breastfeeding women, persons unable to give consent~* Patient with a contraindication to NIV or PEM treatment~* Patient previously treated with anti-PD1 regardless of indication~* Patient treated with anti-PD1 in combination with other anti-tumour treatment~* Patient participating in another interventional clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Controlled Trial of Plantain Powder in Infantile Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children between the ages of 5 months and 2 years of age admitted in the inpatient pediatric ward of Bhatpara Sub divisional Hospital.~2. Infants with more than 3 stools/day which is more frequent than the usual bowel habit of the study subject~3. The consistency of the stool is such that it takes the shape of the container into which it is put in.~4. Duration of symptoms should be less than 14 days.~   -~Exclusion Criteria:~1. Children with bloody diarrhea~2. Children with lethargy, fever or other signs of septicemia~3. Children with shock.~4. Children unable to take medications orally.~5. Children with impaired consciousness.~6. Children whose parents refuse permission to be included in the study.~7. Children who are not usual residents of the area and will not be available for follow up.~8. Children with chronic illnesses such as congenital heart disease, renal failure, chronic liver disease, chronic lung disease, inflammatory bowel disease, immune deficiency etc.~   -

- Gender: ALL
- Minimum Age: 5 Months
- Maximum Age: 24 Months
- Healthy Volunteers: f

Study Arms:
- Green banana (Type: EXPERIMENTAL): Subjects receiving green banana powder.
- Placebo (Type: PLACEBO_COMPARATOR): Microcrystalline cellulose given as placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of one of the following:~  * Chronic myelogenous leukemia~    * Philadelphia chromosome-positive OR~   * Molecular evidence of bcr/abl gene rearrangement~ * Acute myeloid leukemia, acute lymphocytic leukemia, lymphoma, histiocytoses, myelodysplasia, juvenile chronic myelomonocytic leukemia, aplastic anemia, paroxysmal nocturnal hemoglobinuria, or Fanconi's anemia~    * Confirmed by cytochemistry, immunophenotyping, and/or chromosomal abnormalities~ * Multiple myeloma~ * Hereditary immunodeficiency disorders~    * Confirmed by immunologic determination~ * Sickle cell anemia or beta-thalassemia~    * Confirmed by hemoglobin electrophoresis~ * Storage disorders (e.g., Gaucher's disease, Hurler's disease, or metachromatic leukodystrophy)~    * Confirmed by metabolic testing~ * Other non-malignant conditions~* Eligible for allogeneic peripheral blood stem cell or bone marrow transplantation~PATIENT CHARACTERISTICS:~Age:~* 65 and under~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- alloSCT group (Type: None): Patients undergoing allogeneic blood or marrow stem cell transplantation (alloSCT).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Assess the Follow-up of Prostate Cancer Patients Who Have Undergone Radiotherapy Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men with a tumour T1-3 stage prostate cancer and have had radical radiotherapy with curative intent~* Are between six and twelve months post-treatment completion~* Have completed all treatment for prostate cancer (including hormonal deprivation therapy)~* Have no evidence of metastatic disease~* ECOG performance status of between 0-1~* Remains willing to comply with study requirements~* Has maintained contact with an individual general practitioner~Exclusion Criteria:~* Persistent complications resulting from treatment defined as a minimum Grade 3 treatment toxicity~* Unable to complete self-administered questionnaires~* Are currently enrolled in a study that requires specialist follow-up~* Life expectancy of less than 6 months~* Surgery to remove the prostate~* Evidence of biochemical failure

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reviewed by radiation oncologist (Type: None): None
- Reviewed by general practitioner (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy